Bildgebung bei neuroendokrinen Tumoren des Pankreas

Vick, C. Whitley; Zech, Christoph J.; Höpfner, S.; Waggershauser, T.; Reiser, Maximilian

doi:10.1007/s00117-003-0885-8

Cited by 17 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31 Therefore, the diagnostic accuracy of dynamic CT is insufficient, with 64-81% of sensitivity. 32 In our study, only 67% of Some reports have shown that tumor-to-pancreas contrast is usually greatest in the arterial phase in PNEN cases. 17,18,20,31 Therefore, we used arterial phase images to evaluate the enhancement and calculate the CT ratio.…”

Section: Discussioncontrasting

confidence: 54%

Dynamic computed tomography is useful for prediction of pathological grade in pancreatic neuroendocrine neoplasm

Horiguchi

Kato

Shiraha

et al. 2017

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 54%

Dynamic computed tomography is useful for prediction of pathological grade in pancreatic neuroendocrine neoplasm

Horiguchi

Kato

Shiraha

et al. 2017

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…NET cells are characterized by an increased expression of somatostatin receptors, making somatostatin receptor imaging a promising option for detecting NET. 16 – 21 In-111 DTPA octreotide SPECT/CT is currently the standard technique for performing somatostatin receptor imaging. 22 A promising alternative is somatostatin receptor PET/CT using tracers such as Ga-68 DOTATOC, Ga-68 DOTATATE, or Ga-68 DOTANOC.…”

Section: Introductionmentioning

confidence: 99%

Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT

Schreiter

Bartels

Froeling

et al. 2014

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundTo evaluate the clinical efficacy of In-111 DTPA octreotide SPECT/CT and Ga-68 DOTATOC PET/CT for detection of primary tumors in patients with either neuroendocrine tumor of unknown primary (NETUP) or clinically suspected primary NET (SNET).Patients and methods.A total of 123 patients were included from 2006 to 2009, 52 received Ga-68 DOTATOC PET/CT (NETUP, 33; SNET, 19) and 71 underwent In-111 DTPA octreotide SPECT/CT (50; 21). The standard of reference included histopathology or clinical verification based on follow-up examinations.ResultsIn the NETUP group Ga-68 DOTATOC detected primaries in 15 patients (45.5%) and In-111 DTPA octreotide in 4 patients (8%) (p < 0.001); in the SNET group, only 2 primaries could be detected, all by Ga-68 DOTATOC. In patients with NETUP, primary tumors could be found significantly more often than in patients with SNET (p = 0.01). Out of these 21 patients 14 patients were operated.ConclusionGa-68 DOTATOC PET/CT is preferable to In-111 DTPA octreotide SPECT/CT when searching for primary NETs in patients with NETUP but should be used with caution in patients with SNET.

show abstract

Evidence of Hormonal, Laboratory, Biochemical, and Instrumental Diagnostics of Endocrine Tumors of the Pancreas

Ng¹,

Mukherjee²,

Lee³

2015

Pancreatic Cancer, Cystic Neoplasms and Endocrine Tumors

View full text Add to dashboard Cite

Bildgebung bei neuroendokrinen Tumoren des Pankreas

Abstract: None of the various modalities is superior alone, so that it is often necessary to combine them for diagnostic imaging of pancreatic islet cell tumors.

Cited by 17 publications

References 25 publications

Dynamic computed tomography is useful for prediction of pathological grade in pancreatic neuroendocrine neoplasm

Dynamic computed tomography is useful for prediction of pathological grade in pancreatic neuroendocrine neoplasm

Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT

Evidence of Hormonal, Laboratory, Biochemical, and Instrumental Diagnostics of Endocrine Tumors of the Pancreas

Contact Info

Product

Resources

About